BioVie (BIVI) Plunges After Alzheimer’s Drug Fails Phase 3 Due to “Protocol Deviations” at Trial Sites – Hagens Berman
SAN FRANCISCO, Jan. 05, 2024 (GLOBE NEWSWIRE) — Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now. Visit: www.hbsslaw.com/investor-fraud/BIVI Contact An Attorney Now: BIVI@hbsslaw.com 844-916-0895 … Read more